QLT Continues to Divest its Portfolio
By Taskin Ahmed
Pharma Deals Review: Vol 2008 Issue 99 (Table of Contents)
Published: 26 Aug-2008
DOI: 10.3833/pdr.v2008.i99.143 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
As part of its restructuring programme announced on the back of falling revenues of its leading product, Visudyne® (verteporfin), QLT has divested another core asset by licensing out its Atrigel® drug delivery technology to Reckitt Benckiser for US$25 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS